PubMed Health⌕ Search

Biomedical subjects

G L Davis

Publications and source records attributed to G L Davis.

At least 19 recordsLinked to original sources

Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.

The pathogenesis of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is poorly understood, but the cellular immune response is likely to have a major role. Daclizumab, an interleukin-2 receptor (IL-2R) antibody that blunts T-cell activation, leading to a decreased risk for cellular rejection, is used frequently in transplant recipients. The aim of this study is to evaluate the effect of daclizumab therapy on the incidence and severity of recurrent HCV. Forty-one liver transplant recipients (21 patients, HCV positive; 20 patients, HCV negative) at high risk for neurological or renal complications of calcineurin inhibitors were administered daclizumab, mycophenolate mofetil (MMF), and steroids in the early post-LT period, followed by tacrolimus and a steroid taper. All patients were followed up prospectively for graft function and disease recurrence with protocol liver biopsies day 7, month 4, and yearly. Compared with patients without HCV, patients with HCV administered daclizumab had greater 4-month serum alkaline phosphatase, total bilirubin, and alanine aminotransferase (ALT) levels. These biochemical differences resolved by 12 months, except for persistent elevation of ALT levels. Compared with a well-matched HCV control population, patients with HCV administered daclizumab were more likely to have an earlier onset of hepatitis, jaundice, and greater histological activity. Recurrent hepatitis progressed more rapidly in the daclizumab group; 45% developed advanced disease within 1 year. HCV viral load in the daclizumab group was significantly greater at both 4 months and 1 year. Results of this study suggest that the use of adjuvant IL-2R antibodies in combination with MMF in the early peritransplantation period may be associated with early recurrence of hepatitis C and more rapid histological progression of disease.

Adult↗

Current treatment for chronic hepatitis C.

Treatment of chronic hepatitis C has seen phenomenal progress over the last 10 years. The short courses of interferon monotherapy that were used in the early 1990s led to sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of patients. Longer courses improved the durability of those responses slightly. The major recent advance in treatment is the addition of the nucleoside analogue ribavirin to the interferon regimen. Combination of these two drugs for 6 to 12 months results in a sustained virologic response in 30% to 40% of previously untreated patients. Long-acting pegylated interferon has just been approved by the FDA and promises to improve the ease of administration. Furthermore, when used in combination with ribavirin, pegylated interferon increases the sustained virologic response rate to more than 50%.

Antiviral Agents↗

Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.

PURPOSE: Many patients with chronic hepatitis C who are treated with interferon suffer a relapse after an initial response. About half of these patients have a sustained virological response to retreatment with the combination of ribavirin and interferon alfa-2b. The aim of this study was to estimate the cost effectiveness of retreatment with combination therapy versus interferon alone for patients who have previously relapsed after interferon. SUBJECTS AND METHODS: Data from a randomized trial among 345 relapsed patients that compared combination therapy with interferon alone were used to project lifelong clinical and economic outcomes. Natural history and economic estimates (discounted at 3% per year) were based upon published literature, expert panel estimates, and cost and reimbursement data. RESULTS: Compared with retreatment with interferon alone, combination therapy should prolong life expectancy by about 2 discounted quality-adjusted life years (3 life years, undiscounted) while increasing costs modestly. The results were robust, maintaining an advantage to combination therapy in sensitivity analysis for all subgroups and with reasonable variations in all model parameters. CONCLUSION: For patients with chronic hepatitis C who relapse after an initial response to interferon alone, retreatment with the combination of ribavirin and interferon alfa-2b should prolong life and be cost effective.

Adult↗

Current therapy for chronic hepatitis C.

Chronic hepatitis C virus infection is common in the United States with an estimated prevalence of 2.7 million persons. Fortunately, the incidence of new infections has markedly declined in recent years and the natural history of chronic hepatitis usually only results in significant progression after several decades of infection. However, the majority of chronically infected patients acquired their infections more than 20 years ago; these patients with long-standing chronic hepatitis are now presenting in increasing numbers with decompensated cirrhosis and the need for liver transplantation. Cirrhosis caused by chronic hepatitis C is now the most common indication for liver transplantation. Interferon monotherapy became clinically available 10 years ago but resulted in sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of treated patients. The recent use of the combination of interferon with the nucleoside analogue ribavirin for 6-12 months results in a sustained virological response in 30%-40% of previously untreated patients. The response to this combination therapy is also excellent in patients who had initially responded to interferon monotherapy and later relapsed. Furthermore, some recent studies suggest that a small proportion of patients who failed to respond to a prior course of interferon (primarily noncirrhotic patients with low levels of virus and genotypes other than 1) may also benefit from retreatment with this combination.

Antiviral Agents↗

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.

BACKGROUND & AIMS: Interleukin (IL)-10 is a cytokine that down-regulates the proinflammatory response and has a modulatory effect on hepatic fibrogenesis. The aim of this study was to determine the effect of IL-10 on hepatic injury in patients with chronic hepatitis C. METHODS: Twenty-four patients with chronic hepatitis C who had not previously responded to interferon-based therapy were enrolled in a randomized, double-blinded 2-dose trial in which they received either 4 or 8 microgram/kg IL-10 subcutaneously daily for 90 days. Liver biopsies were performed before and at the end of therapy. RESULTS: IL-10 was well tolerated with 22 patients completing the study. Serum ALT levels normalized in 19 of 22 patients by the end of therapy and were sustained in 5 of 22. Hepatic inflammation decreased in 19 of 22 patients, with 11 having a decrease by >/=2. Fibrosis decreased in 14 of 22 patients (mean change, 3.6-2.6; P = 0.001). There was no change in serum HCV RNA levels. IL-10 therapy was associated with changes in serological markers, suggesting a reduction of immune response and fibrogenesis. CONCLUSIONS: IL-10 therapy is safe and well tolerated in patients with chronic hepatitis C. Although it has no apparent antiviral activity, IL-10 normalizes serum ALT levels, improves liver histology, and reduces liver fibrosis in a large proportion of patients receiving treatment. Therefore, IL-10 may have therapeutic potential in patients with chronic hepatitis C patients who do not respond to interferon-based therapy.

Alanine Transaminase↗

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

The extent of liver fibrosis is an important prognostic factor in patients infected with hepatitis C virus. Administration of a combination of interferon and ribavirin produces a superior viral clearance response rate than interferon alone. The effect of this combination regimen on hepatic fibrosis has not been established. To determine the impact of combination regimen or interferon alone on the progression of liver fibrosis we pooled individual data of 1,509 patients with pretreatment and post-treatment biopsies from 3 randomized trials. Fibrosis progression and regression rates between biopsies were calculated by the Kaplan-Meier method and by the fibrosis progression rate per year. The percentage of patients without significant fibrosis (stage 0 or 1) at 96 weeks was 68 +/- 4% (mean +/- SE) when treated by combination regimen for 48 weeks, 64 +/- 4% by interferon alone for 48 weeks, 42 +/- 7% by combination regimen for 24 weeks (lower than both 48-week regimens P <.001), and 24 +/- 9% interferon alone for 24 weeks (lower than the combination regimen for 24 weeks; P =.02). Three factors were independently associated with fibrosis reduction: sustained viral response, duration of treatment, and baseline fibrosis stage (all P <.001 in proportional hazards regression model). These results show that interferon and ribavirin combination therapy significantly reduces the rate of fibrosis progression in patients with hepatitis C. This effect was most prominent in patients who achieved a virologic response, those receiving 48 weeks of therapy, and in patients with significant fibrosis at baseline.

Adult↗

Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin.

Increased levels of hepatic iron may impair the response of patients with chronic hepatitis C to treatment with interferon-alfa, but combination therapy with ribavirin has demonstrated efficacy in the treatment of hepatitis C. When used alone or with interferon-alfa, ribavirin may cause a dose-dependent reversible hemolytic anemia. We compared the extent and cellular localization of iron deposition in liver tissue from biopsy specimens obtained before and after 36 weeks of therapy with ribavirin or placebo for 59 patients with chronic hepatitis C. Paired slides were available for review from 26 ribavirin and 27 placebo recipients. Iron deposition was assessed using coded slides stained with Perls Prussian blue and was semi-quantitated in hepatocytes, Kupffer cells, and areas of fibrosis. The overall iron score fell by 0.96 in the placebo group and increased 1.69 in the ribavirin recipients. Iron was deposited mainly in hepatocytes; the hepatocyte iron score increased from 2.19 to 3.81 in the ribavirin group. The amount of iron staining in Kupffer cells declined in the placebo group and increased slightly in the ribavirin group. Iron changes in areas of fibrosis were minor and did not differ between groups. Increased total hepatic iron deposition occurred during a 9-month course of ribavirin. Ribavirin-associated hemolysis deposits iron preferentially in hepatocytes. This increased deposition of hepatic iron does not seem to affect the biochemical or histologic response to ribavirin therapy but may have implications for hepatocyte susceptibility to future injury.

Alanine Transaminase↗

A yeast genetic assay for caspase cleavage of the amyloid-beta precursor protein.

A functional assay for proteolytic processing of the amyloid precursor protein (APP) was set up in yeast. This consisted of a membrane-bound chimeric protein containing the beta-secretase cleaved C-terminal fragment of APP fused to the Ga14 transcription factor. Using this chimera in a GAL-reporter yeast strain, an expression library of human cDNAs was screened for clones that could activate the GAL-reporter genes by proteolytic processing of the membrane-bound APP-Gal4. Two human proteases, caspase-3 and caspase-8, were identified and confirmed to act by a mechanism that involved proteolysis at the site in the APP-Gal4 chimera that corresponded to the natural caspase cleavage site in APP, thus linking a readily scorable phenotype to proteolytic processing of APP. The activation of caspase-3 involved a mechanism that was independent of aspartic acid residue 175 at the cleavage site normally required for processing of caspase-3.

Amyloid beta-Protein Precursor↗

Hemostatic changes associated with normal and abnormal pregnancies.

Routine hemostatic laboratory tests lack sensitivity and are of little value in the detection of the pregnancy associated hypercoagulable conditions. Assays for F 1 + 2, AT levels, TAT complex, APC activity, FPA, D-Dimers, tPA, plasminogen, PAI 1, and PAI 2 are more specific for fibrin formation and lysis. Monitoring these tests along with fibrinogen and platelet counts provides important information for the early detection of hemostatic activation and for monitoring the severity of the condition. Early detection and therapy is essential for limiting the deleterious complications of pregnancy. Advances in research, the development of new tests such as the TM assay and gene analysis, as well as highly skilled personnel, are required for the providing of quality pre and postnatal healthcare.

Blood Coagulation Tests↗

Hepatitis C virus genotypes and quasispecies.

Genetic heterogeneity is a hallmark of the hepatitis C virus, as a result largely of the infidelity of viral RNA-dependent RNA polymerase. Random nucleotide substitutions are introduced at a very high rate. The existence of genotypes was confirmed by statistical and mathematical techniques, and the relation of the genotypes to each other has been determined. There are six major genotypes, each with multiple subtypes. Isolates of the same genotype have an average sequence homology of 95%, but different genotypes have sequence similarity of approximately 65% on average. The nucleotide sequence in portions of the hepatitis C viral genome, including the 5' noncoding region, part of the core gene, and other nonstructural proteins, is highly conserved. Genotype analysis typically utilizes these highly conserved regions. There are many techniques for determining viral genotype, and in general, concordance between techniques is good. Methods most commonly used for assigning hepatitis C virus (HCV) genotypes in clinical practice include restriction fragment length polymorphism analysis and the reverse hybridization line probe assay (LiPA; Innogenetics, Ghent, Belgium). The worldwide distribution of HCV genotypes has been determined; some genotypes are highly characteristic of certain areas. The most common subtypes, 1 and 2, are less genetically diverse than the others and are more widely distributed. The impact of genotype on disease course is controversial, but recent data suggest that there is a genotype-dependent differential response to therapy. Quasispecies refers to evolution of a highly related but genetically heterogeneous population of HCV isolates. The pathobiological and clinical implications of HCV quasispecies are poorly understood.

Genome, Viral↗

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

Hepatitis C infects nearly 4 million Americans. Most have chronic hepatitis C (CHC), which progresses to cirrhosis in about 20% of patients. Interferon treatment leads to transient responses in about 40% of patients and apparent eradication of infection in 7% to 40% of patients. In this report, we document the impact of CHC on health-related quality of life (HQL), and changes in HQL among treatment responders. Three hundred twenty-four CHC patients from 10 countries who had relapsed after responding to interferon-alfa therapy were randomized to monotherapy (IFN alfa-2b + placebo) or combination therapy (IFN alfa-2b + ribavirin), treated for 24 weeks, and followed up for 24 weeks. HQL was assessed using the Hepatitis Quality of Life Questionnaire (HQLQ), containing the generic SF-36 Health Survey, three additional generic scales, and two hepatitis-specific scales. Before treatment, CHC patients were impaired in 5 of 8 SF-36 concepts (physical functioning, role-physical, general health, vitality, and social functioning) in comparison with matched population norms. Sustained virological response (SVR) to treatment yielded improvements on three generic scales (vitality, social functioning, and health distress) and the CHC-specific health distress scale. Overall response to treatment (SVR plus histological improvement) yielded the same pattern of improvements with additional gains in generic general health and CHC-specific limitations. Successful treatment of CHC improved HQL as measured by both CHC-specific and generic measures of functional health and well being.

Female↗

New schedules of interferon for chronic hepatitis C.

Current treatment regimens with either long-term interferon monotherapy or interferon-ribavirin combination achieve sustained response rates of 40-50%. Options to improve the sustained response to interferon include longer treatment duration, higher fixed doses throughout the course of therapy, de-escalating strategies in which more intensive treatment is given during the initial weeks of treatment (so-called induction dosing) or escalation strategies in which the dose is progressively increased until a response occurs. Published literature supports the use of a treatment period of at least 12 months. Although higher doses which are fixed throughout the treatment course result in a moderate increase in sustained response rate, this may not be justified by the cost and added side effects. Although high dose induction strategies may result in a more rapid decline in serum HCV RNA levels, it is not yet known whether this will result in better longterm outcome. Preliminary evidence suggests that the benefit may be confined to subgroups of patients who might be predicted to have a poor response to standard therapy, such as those with high pre-treatment viral levels.

Antiviral Agents↗

Combination treatment with interferon and ribavirin for chronic hepatitis C.

Interferon was the first drug shown to be effective in patients with chronic hepatitis C, but initial treatment regimens achieved sustained loss of virus in only a small minority of patients. The combination of IFN with ribavirin now makes sustained response rates of 30% to 40% possible. This is quite a remarkable achievement for a pharmacologic treatment of a chronic viral infection. It is now reasonable to assume that early treatment and eradication of chronic hepatitis C might reduce the growing burden of hepatitis C and its complications on the healthcare system. Future researchers will strive to optimize combination treatment regimens. Longer treatment courses and intensified induction regimens using either daily dosing, high doses, or both may improve long-term response, but this remains speculative. Other forms of IFN may improve response or increase the ease of drug administration. Conjugation of biologic compounds to polyethylene glycol can result in significant prolongation of plasma half-life while maintaining the properties of the parent molecule. Some biologic properties may be altered, however, so pegylated IFN must continue to be evaluated in clinical trials. There is limited clinical data on other recombinant or natural interferons in combination with oral ribavirin, however, these may prove to be equally effective. Combinations of IFN with one or more other antiviral, anti-inflammatory, or immune modulatory agents will need to be studied. Although amantidine is not effective against hepatitis C as a single agent or in combination with IFN, the combination of IFN, ribavirin, and rimantidine has been shown to have antiviral activity superior to the IFN-ribavirin combination against influenza virus and possibly against HCV.

Alanine Transaminase↗

Hepatitis G virus infection in renal transplant recipients.

To determine the prevalence and clinical significance of hepatitis G virus (HGV)/GB virus C (GBV-C) infection in renal transplant recipients, prospectively collected serum samples from a cohort of cadaveric renal transplant patients were studied for the presence of HGV RNA using a sensitive reverse transcription 'nested'-polymerase chain reaction (RT-PCR) based on primers derived from the 5' untranslated region. All positive PCR amplicons were sequenced bidirectionally and aligned. The nucleotide substitution rate was estimated by the 6-parameter method, and a phylogenetic tree was constructed using the Neighbour-joining method. HGV RNA was detected in 11/93 (12%) patients pretransplant and in 15/90 (17%) patients 1-4 years post-transplant. All PCR amplicons were confirmed to be specific for HGV by sequencing. Phylogenetic tree construction revealed that 17 PCR amplicons had sequences related to HGV and one had a sequence related to GBV-C. Two HGV RNA-positive patients pretransplant became HGV RNA negative post-transplant, and seven HGV RNA-negative patients pretransplant became HGV RNA positive post-transplant. There was no relationship between hepatitis C virus (HCV) and HGV infection. There were also no differences in age, gender distribution, ethnic origin, the total number of blood units transfused and either graft or patient survival between patients who were positive or negative for HGV RNA. We conclude that HGV infection is common among renal transplant candidates and recipients. Most of the isolates had sequences related to the HGV prototype. HGV infection does not appear to adversely affect clinical outcome in renal transplant recipients during early follow-up.

5' Untranslated Regions↗